Altheos is a technology company.
Altheos has raised $33.0M across 2 funding rounds.
Altheos has raised $33.0M in total across 2 funding rounds.
Altheos, Inc. was an early-stage biopharmaceutical company focused on developing novel small molecule drugs, particularly eye drop therapies for glaucoma and ocular hypertension. It targeted promising, well-differentiated compounds like ATS-907, a Rho kinase (ROCK)-selective inhibitor to reduce elevated intraocular pressure (IOP).[1][2][3][4][6] The company served patients with primary open-angle glaucoma, addressing unmet needs in next-generation topical treatments through its pipeline, including Phase 2a clinical trials.[4] Altheos raised $20 million in Series A financing (later expanded to $32.5 million via tranches tied to milestones) from investors like Bay City Capital, Novo A/S, and Canaan Partners, showing early growth momentum before apparent inactivity.[3][4]
Altheos, Inc. emerged as a biotech startup in the biopharmaceutical space, with roots in South San Francisco, licensing ROCK inhibitor compounds from Asahi Kasei Pharma.[4] Key milestones included completing a $20 million Series A round to advance glaucoma treatments and initiating a Phase 2a clinical trial for lead candidate ATS-907 in 2012, dosing its first patient.[3][4] An additional $12.5 million tranche brought total funding to $32.5 million, supporting pipeline development amid early traction in ophthalmology.[4] Founders and exact founding year are not detailed in available records, but the company's focus evolved around small molecule innovation for eye diseases.[1][2]
(Note: A separate entity, Alethos Technologies, focuses on safety and security tech, but matches the query's "technology company" less directly than Altheos' biotech innovations.[5])
Altheos rode the early 2010s wave of targeted small molecule therapies in ophthalmology, capitalizing on ROCK inhibitors as a next-generation alternative to existing IOP-lowering drops amid rising glaucoma prevalence.[3][4] Timing aligned with biotech investor interest in specialty pharma, where focal therapies addressed neovascularization and fibrosis—trends now amplified by aging populations and demand for non-invasive treatments.[4] Market forces like licensing deals (e.g., from Asahi Kasei) favored nimble startups, positioning Altheos to influence eye care innovation, though its footprint appears limited post-2012 trials.[1][2]
Altheos exemplified early biotech promise in glaucoma innovation but shows no recent activity, suggesting acquisition, pivot, or dormancy—common in pre-clinical ventures. Future trends like AI-driven drug discovery and sustained-release eye therapies could revive similar ROCK-focused pipelines, potentially evolving Altheos' legacy through acquirers advancing ATS-907 analogs. Watch for biotech consolidation, where its investor network might fuel comebacks in ophthalmology's $10B+ market. This early mover's story underscores biotech's high-stakes race from Series A to market.
Altheos has raised $33.0M in total across 2 funding rounds.
Altheos's investors include Canaan Partners, Pivotal bioVenture Partners.
Altheos has raised $33.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in February 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2012 | $13.0M Series A | Canaan Partners, Pivotal bioVenture Partners | |
| Apr 1, 2010 | $20.0M Series A | Canaan Partners, Pivotal bioVenture Partners |